| 
						  | 
					 
					
						| 
					
						
						 | 
					 
					
						
						Which Medical Devices  require to Clinical Trial before SFDA approval
 
  | 
					 
					
						|   | 
					 
					
						
							While applying for MD product initial registration of Class II and Class 
	III, clinical trial information has to be submitted. The drug regulatory 
	authorities of provinces, autonomous regions and municipalities directly 
	under the central government are responsible for the inspection and approval 
	of the clinical trial of class II medical devices in their own 
	administrative regions. The State Food and Drug Administration is 
	responsible for the inspection and approval of clinical trial of class III 
	medical devices.  
	 
	Clinical trial shall be conducted in the medical institutions designated by 
	the drug regulatory authorities of the government at provincial level and 
	above. The medical institutions shall conduct the clinical trial, in 
	accordance with SFDA Oder 5 "Provisions for Clinical Trials of Medical 
	Devices" taken go into effect as of April 1, 2004. The qualification of 
	medical institutions engaged in the clinical trial shall be certified by the 
	drug regulatory authority, jointly with Ministry of Health. 
	 
	Based on the different condition that whether it has been already placed 
	into market overseas or this enterprise or applicant has already registered 
	equivalent products in China, the detail requirements of clinical trial 
	information are different and clarified in annex 12 of SFDA order 16 
	"Provision for Medical Devices Registration" taken into effect as of August 
	9, 2004. 
	 
	If the clinical trial of medical devices conducts in China, the information 
	provided in clinical trial report includes contracts, protocols, and the 
	final summarized reports. Whenever necessary, SFDA may require the applicant 
	to submit the Notice, Informed Consent and original test records. 
	 
	Based on the above requirements of MD clinical trials, clinical trials of 
	IVD reagents specifies the detail requirements in SFDA Notice [2007]229 
	"Management Method of In Vitro Diagnostic Reagents Registration (Interim)" 
	taken effect as of June 1, 2007. The details contain the quality of detected 
	product, detection unit and specifications, the qualification and quantity 
	of clinical trial institution and the minimum quantity of specimens. 
	Moreover the detail technical requirements of basic principle, research 
	method, specimen volume and the establishment of clinical research report 
	are clarified in "Technical Guideline Clinical Research for IVD Reagent" 
	implemented on the same day. 
 | 
					 
					
						|   | 
					 
					
						|   | 
					 
				 
				 
				 | 
				
				
  |